FDA Draft Guidance Would Require Abuse Deterrence For Generic Opioid Drugs
SILVER SPRING, Md. — The Food and Drug Administration on March 24 said it has issued a draft guidance that would require makers of generic opioid drugs to develop abuse-deterrent formulations....To view the full article, register now.
Already a subscriber? Click here to view full article